NASDAQ:PRLD
Prelude Therapeutics Inc
Prelude Therapeutics Inc's revenue grew 73.4% in fiscal 2025 to $12.1M while operating margin rose to −861.3%. Free cash flow was −$56.4M, −464.3% of revenue, and the diluted share count rose 1.5%.Summary generated from Prelude Therapeutics Inc's SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$12.1M
Revenue growth+73.4%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−861.3%
Net margin−819.6%
ROICn/a
Return on equity−99.5%
Debt / equityn/a
Free cash flow−$56.4M
FCF margin−464.3%
Share count change+1.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | 7 | 12 |
| Operating income | −114 | −124 | −132 | −140 | −105 |
| Net income | −112 | −115 | −122 | −127 | −99 |
| Free cash flow | −86 | −87 | −111 | −104 | −56 |
Recent filings
- 8-KRegulation FD disclosure
Sep 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jun 10, 2026 - 4Insider transaction report
Jun 10, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KResults of operations and financial condition
May 12, 2026